RSV-F vaccine: Additional Phase II data

Additional data from the double-blind, U.S. Phase II Study M201 in 330 women of child-bearing age showed that intramuscular RSV-F vaccine on days 0 and 28 with and without an aluminum phosphate adjuvant reduced the incidence of acute RSV infection by 50% between day 56 and 112 vs. placebo (10% vs. 20%, p<0.004). Data were presented at the Vaccine & ISV meeting in Philadelphia. Novavax previously reported data that 60 and 90 Ug doses of the RSV-F vaccine on days 0 and 28 with and without an aluminum phosphate adjuvant were generally well tolerated with no vaccine-related serious adverse events reported (see BioCentury, April 8, 2013). The vaccine is also in Phase II testing to vaccinate against RSV infection in healthy women in the third trimester of pregnancy and in healthy elderly subjects. ...